Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
New study presents a human-relevant stress model for assessing potential therapeutics
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Subscribe To Our Newsletter & Stay Updated